ACG临床指南:肠易激综合征的管理
这是美国胃肠病学会(ACG)首部采用GRADE方法制定的肠易激综合征(IBS)管理临床指南。指南推荐采用阳性诊断策略、血清学检测排查乳糜泻、粪便钙卫蛋白排查炎症性肠病,并推荐限制性低FODMAP饮食、氯通道激活剂/鸟苷酸环化酶激活剂、利福昔明及肠道导向心理治疗。
要点
- 推荐阳性诊断策略而非排除诊断策略,以缩短启动适当治疗的时间。
- IBS伴腹泻症状者应检测血清学排除乳糜泻,并检测粪便钙卫蛋白排除炎症性肠病。
- 推荐限时试用低FODMAP饮食改善整体症状,并推荐氯通道激活剂/鸟苷酸环化酶激活剂治疗便秘型IBS、利福昔明治疗腹泻型IBS。
核心结论
- 推荐采用阳性诊断策略以缩短启动适当治疗的时间。
- 推荐对IBS伴腹泻症状者进行血清学检测排除乳糜泻。
- 推荐对疑似IBS伴腹泻症状者检测粪便钙卫蛋白排除炎症性肠病。
- 推荐对IBS患者限时试用低FODMAP饮食以改善整体症状。
- 推荐使用氯通道激活剂和鸟苷酸环化酶激活剂治疗便秘型IBS的整体症状。
研究设计与样本
- 美国胃肠病学会(ACG)采用GRADE方法制定的首部IBS管理临床指南。
- 采用改良Delphi法达成共识。
关键数值与推荐
- 推荐阳性诊断策略而非排除诊断策略(推荐强度:建议)。
- 建议对IBS伴腹泻症状者进行血清学检测排除乳糜泻(推荐强度:建议)。
- 建议对疑似IBS伴腹泻症状者检测粪便钙卫蛋白排除炎症性肠病(推荐强度:建议)。
- 推荐限时试用低FODMAP饮食改善整体症状(推荐强度:推荐)。
- 推荐氯通道激活剂和鸟苷酸环化酶激活剂治疗便秘型IBS整体症状(推荐强度:推荐)。
临床怎么用
- 对IBS患者采用阳性诊断策略,以尽早启动适当治疗。
- 对IBS伴腹泻症状者,通过血清学检测排除乳糜泻、粪便钙卫蛋白排除炎症性肠病。
- 根据IBS亚型选择药物:便秘型可用氯通道激活剂/鸟苷酸环化酶激活剂,腹泻型可用利福昔明。
- 可考虑限时试用低FODMAP饮食及肠道导向心理治疗改善整体症状。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Irritable bowel syndrome (IBS) is a highly prevalent, chronic disorder that significantly reduces patients' quality of life. Advances in diagnostic testing and in therapeutic options for patients with IBS led to the development of this first-ever American College of Gastroenterology clinical guideline for the management of IBS using Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Twenty-five clinically important questions were assessed after a comprehensive literature search; 9 questions focused on diagnostic testing; 16 questions focused on therapeutic options. Consensus was obtained using a modified Delphi approach, and based on GRADE methodology, we endorse the following: We suggest that a positive diagnostic strategy as compared to a diagnostic strategy of exclusion be used to improve time to initiating appropriate therapy. We suggest that serologic testing be performed to rule out celiac disease in patients with IBS and diarrhea symptoms. We suggest that fecal calprotectin be checked in patients with suspected IBS and diarrhea symptoms to rule out inflammatory bowel disease. We recommend a limited trial of a low fermentable oligosaccharides, disacchardies, monosaccharides, polyols (FODMAP) diet in patients with IBS to improve global symptoms. We recommend the use of chloride channel activators and guanylate cyclase activators to treat global IBS with constipation symptoms. We recommend the use of rifaximin to treat global IBS with diarrhea symptoms. We suggest that gut-directed psychotherapy be used to treat global IBS symptoms. Additional statements and information regarding diagnostic strategies, specific drugs, doses, and duration of therapy can be found in the guideline.
引用
- Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021. PMID: 33315591. doi:10.14309/ajg.0000000000001036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。